



SOLVAY

asking more from chemistry®

Q4 & FY 2015 RESULTS

February 25, 2016

Forenote

Cytec has not contributed to the 2015 Group Income or cash flow statements, as its results and cash flows for the period between 09/12/2015 (acquisition date) and 31/12/2015 are not material. However, in order to provide a framework reference going forward, this report includes unaudited pro forma financial data including Cytec, as if the acquisition had taken place on 01/01/2015.

Besides IFRS accounts, Solvay also presents Adjusted Income Statement performance indicators that exclude non-cash Purchase Price Allocation (PPA) accounting impacts related to the Rhodia acquisition.

From Q1 2016, the Group's results will be presented on an IFRS and Underlying basis only. The current definition of REBITDA will equate to Underlying EBITDA going forward.

SAFE HARBOR

This presentation may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this presentation is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&D projects and other unusual items.

Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements

This document does not constitute an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities.

Overview

- **Transformation acceleration & delivery**
- Financial highlights
- Priorities and Outlook



SOLVAY

asking more from chemistry®

TRANSFORMATION ACCELERATION & DELIVERY



2015

- Step-change in portfolio upgrade
- Strong excellence delivery
- Solid earnings growth
- Enhanced sustainability commitments




Dividend up



2015

A STEP-CHANGE IN OUR TRANSFORMATION

Much stronger portfolio



More global

More diversified

Higher sustainability

More innovative

More resilient




FURTHER UPGRADE TO COME FROM DIVESTITURES


AN ENHANCED BUSINESS PROFILE MORE DIVERSIFIED & MORE RESILIENT

Solvay pro forma 2015 (including Cytec)

Balanced
regional profile



Diversified & higher growth
end-markets



30,910
employees



53
countries



145
industrial sites



21
main R&I centers

STRATEGICALLY COHERENT BUSINESS SEGMENTS DRIVING RESULTS

Solvay pro forma 2015 (including Cytec)

Net Sales
€ 12.4 bn

REBITDA
€ 2,336 m

REBITDA margin
19%

FCF
€ 492 m

Capex
€ 1,092 m

CFROI
6.1%

GROWTH ENGINES

ADVANCED MATERIALS

High performance materials, providing solutions for sustainable mobility: **light-weighting**, CO₂ and energy efficiency

Specialty Polymers **#1**

Composite Materials **#2**

Special Chem **#1**

Silica **#1**

ADVANCED FORMULATIONS

Customized specialty formulations in **surface chemistry**, optimizing efficiency, minimizing environmental impact

Novecare **#1**

Technology Solutions **#1**

Aroma Performance **#1**

RESILIENT CASH CONTRIBUTOR

PERFORMANCE CHEMICALS

Leading positions in chemical intermediates, through scale and technology

Soda Ash & Derivatives **#1**

Peroxides **#1**

Acetow **#4**

Coatis **#1**

FUNCTIONAL POLYMERS

Leading regional positions in functional polymers, with focus on excellence


Polyamide **#3**

Chlorovinyls **#2**

UNIQUE LIGHTWEIGHTING OFFERING DRIVING SUSTAINABLE MOBILITY

Solvay's unique portfolio

BROADEST HIGH-PERFORMANCE POLYMER RANGE




PROVIDING SOLUTIONS FOR

- Lightweight materials for transportation
- Production cycle time acceleration
- Total cost reduction



Driving sustainable mobility

AUTOMOTIVE



AEROSPACE



UNDERPINNED BY

- Reduction of fuel consumption
- Decreasing CO₂ emissions
- Increasing driving autonomy



BROAD OFFERING OF INNOVATIVE FORMULATIONS MODIFYING SURFACE CHEMISTRY & FLUID BEHAVIORS



NEXT GENERATION
SOLUTIONS FOR HOME
FABRIC & PERSONAL CARE

COMPETITIVE technology portfolio



- Leader in global markets & niche specialty technologies:


MILD
SURFACTANTS

NATURAL (GUAR) &
SYNTHETIC POLYMERS

PHOSPHINES



IMPROVED RECOVERY
AND YIELD

- 
- Supplying OEMs, Tier 1 B2B and global B2C brand-owners
 - Highly competitive global on-pipe alkoxylation footprint

ENHANCED EFFICIENCY
FERTILIZERS

REDUCED environmental impact



COST EFFICIENT
FRICTION REDUCERS



USING CUSTOMER INTIMACY & MARKET FOCUS AS CRITICAL SUCCESS FACTORS

EXCELLENCE SCOPE EXPANDED

STRONG DELIVERY

3- year excellence targets ...

Operational
€ 400 m

Innovation
€ 270 m

Commercial
€ 130 m

... by YE 2015

~80% achieved

~70 % achieved

~80% achieved

> € 600m delivered in 2 years
on track to deliver € 800 m by 2016


Expected impact on 2016 REBITDA (vs 2013 base), excluding Cytec

→ **FAST DELIVERY, MORE POTENTIAL**



STRENGTHENED SUSTAINABILITY COMMITMENTS

SOLVAY'S
COMMITMENT
BY 2025



Overview

- Transformation acceleration & delivery
- **Financial highlights**
- Priorities and Outlook



SOLVAY

asking more from chemistry®

SOLID PERFORMANCE IN 2015 ON FINANCIAL & SUSTAINABILITY LEVEL

Solvay stand-alone

REBITDA	1,955 € m	↗ 9.6%	Safety	0.77 MTAR ^[2]	✓ (20)%
Net income Group share, Adjusted	477 € m	156 in 2014	GHG Emissions / REBITDA	7.26 kg CO ₂ / €	✓ (10)%
FCF Free Cash Flow	387 € m	656 in 2014	SPM Sustainable Portfolio Management	33% Sustainable solutions	✓ 8pp
CFROI Cash Flow Return On Investment ^[3]	6.9 %	→	Employee engagement index	75 %	✓
Dividend Gross (recommended)	3.3 € / share	↗ 3.3%	Employees involved in societal actions	10 %	✓

€ 10.6 € billion	Factory 969 € m	Flask 18% new sales ratio ⁽¹⁾	Person 26,350 headcount	Globe > 50 countries
Net sales	Capex	R&I	Employees	Footprint

2015 Solvay stand-alone figures
(with evolution vs 2014)

[1] New sales ratio =
sales from products developed or
improved in last 5 years


[2] MTAR =
Medical Treatment
Accident Rate

[3] CFROI = $\frac{\text{REBITDA} - \text{rec. capex} - \text{tax}}{\text{Gross assets} + \text{working capital}}$
with Gross assets at replacement value including goodwill

FOREX IMPACT ON SALES MORE THAN OFFSET MAJOR ADJUSTMENTS IN OIL & GAS AND ACETATE TOW MARKETS

Net Sales FY 2015

Solvay stand-alone
in € m



➤ **Supportive forex:** USD mainly

- 2014: 1.33 \$/€
- 2015: 1.11 \$/€

➤ **Volumes down** as contraction in acetate tow and oil & gas markets offset innovation driven-demand


- Advanced Formulations
- Advanced Materials
- Performance Chemicals
- Functional polymers

➔ **Pricing stable** despite lower raw material prices

INNOVATION, EXCELLENCE & FOREX SUPPORT REBITDA GROWTH DESPITE SOME MAJOR MARKET HEADWINDS

REBITDA FY 2015

Solvay stand-alone
in € m



➤ **Supportive forex**
USD mainly

➤ **Pricing power**
across segments
underpinned by
Excellence

➤ **Fixed costs up**
8 new plants
commissioned
➤ **Excellence** offset
inflation

**OVERALL
EXCELLENCE
MEASURES EXCEED
€ 300 M**

NET INCOME REFLECTING PORTFOLIO UPGRADE EXCEPTIONALS

UNDERLYING NET INCOME UP 9%

P&L Solvay stand-alone <i>in € m</i>	Adjusted	
	FY 2015	FY 2014
Net sales	10,578	10,213
REBITDA	1,955	1,783
Depreciation & Amortization	(733)	(641)
Other elements	(35)	(72)
Non-recurring items	(245)	(308)
EBIT	941	761
Net financial charges	(226)	(309)
Income taxes	(135)	(120)
Result continuing operations	580	333
Result discontinued operations	(55)	(244)
Net income	525	89
Non-controlling interests	(48)	67
Net income Solvay share	477	156
Underlying	680	622

Adjusted: Excluding non-cash PPA accounting impacts related to the Rhodia acquisition

Underlying: Excluding non-cash PPA and other exceptionals, as well as reclassifying hybrid bonds dividends as financial charges

Non-recurring costs

- € (130) m related to Cytec acquisition
- Restructuring expenses and impairments, environmental provisions

Net financial charges lower due to discount rate changes

- Net debt charges stable
- Lower discounting costs for pension and environmental provisions due to higher discount rates

Income taxes up with higher results

- € 107 m exceptional impact (e.g. recognition of deferred tax assets)
- Underlying tax rate of 30%, vs 35% in 2014

Discontinued operations result up due to important impairments in chlorovinyls

- LatAm Indupa in 2015;
- European Chlorovinyls in 2014 (partly offset by capital gain on sale of Eco Services)

COMBINED ENTITY PRO FORMA 2015

PROVIDING ROBUST BASE FOR GROWTH

P&L 2015 pro forma (Solvay + Cytec)

(in € m)	Pro forma combination					
	Solvay stand-alone	Cytec stand-alone	Funding Cytec	IFRS	Adjustments [1]	Underlying
Net sales	10,578	1,800	-	12,378	-	12,378
REBITDA	1,955	381	-	2,336	-	2,336
Depreciation & Amortization	(842)	(311)	-	(1,153)	367	(786)
Other elements			-		35	-
Non-recurring items	(245)	(11)	-	(256)	256	-
EBIT	833	59		892	658	1,550
Net financial charges	(226)	(32)	(66)	(324)	(120)	(444)
Income taxes	(97)	(3)	37	(63)	(268)	(331)
<i>Tax rate</i>	17%	12%		12%	-	30%
Result from continuing operations	509	24	(29)	504	270	774
Result from discontinued operations	(55)	(2)	-	(56)	115	59
Net income	454	23	(29)	448	385	833
Non-controlling interests	(48)	-	-	(48)	(17)	(65)
Net income Solvay share	406	23	(29)	400	368	768
Basic EPS from continuing operations (in €)	5.57			4.45	2.53	6.98
Basic EPS (in €)	4.85			3.85	3.54	7.40
CFROI						6.1%

CYTEC DELIVERING ON EARNINGS GROWTH TARGETS DRIVEN BY ADVANCED TECHNOLOGY & IMPROVED PRODUCTIVITY



Represented according to US GAAP in USD
excluding one-off items and Corporate & unallocated costs

Cytec (in US\$)	Net sales			Operating earnings			Operating margins		
	FY 2015	FY 2014	% vov	FY 2015	FY 2014	% vov	FY 2015	FY 2014	% vov
Aerospace Materials	1,028	1,000	3%	205	178	15%	20%	18%	2.1pp
Industrial Materials	268	326	(18)%	10	31	(68)%	4%	9%	(5.8)pp
In Process Separation	432	411	5%	117	96	22%	27%	23%	3.8pp
Additive Technologies	268	271	(1)%	37	34	9%	14%	13%	1.3pp
Total	1,996	2,008	(1)%	368	338	9%	18%	17%	1.6pp

Strong performance of **Aerospace Materials** and **In Process Separation**, with increased margins

- Productivity improvements in Aerospace Materials
- Favorable product mix in In Process Separation
- Lower raw material costs

Weaker performance at **Industrial Materials** after strong 2014


- Demand impacted by softer market conditions across greater Europe
- Challenges from new ERP start-up

PEAK GROWTH INVESTMENTS IN 2015 ...

Capex

Solvay stand-alone
Continuing operations
in € m

■ Growth capex
■ Maintenance capex



→ 2015

- 8 new facilities commissioned
- HPPO Saudi Arabia
→ ~9 month delay

Growth projects ^[1]

Advanced Formulations

2013	2014	2015
	Specialty surfactant plant in Germany	✓
	Alkoxylation plant in U.S.	✓
	Alkoxylation plant in Singapore	✓
	Vanillin plant in China	✓


Advanced Materials

	Fluoropolymers plant in China: phase 1 / phase 2	✓ □
		PEEK exp. India ✓
		PEEK plant in USA □
	Silica plant in Poland	✓
		Silica plant in Korea □

Performance Chemicals

	Bicarbonate plant in Thailand	✓
	Soda ash expansion in U.S.	✓
	HPPO plant in Saudi Arabia	□
	H ₂ O ₂ plant in China	✓

Growth project in growth regions




... TO REDUCE GOING FORWARD WITH INTENSIFIED FOCUS ON CASH GENERATION

Selective investments for future value creation

Cash conversion
 $\frac{\text{REBITDA} - \text{capex}}{\text{REBITDA}}$

Capex
Continuing operations
in € m

■ Growth capex
■ Maintenance capex



→ 2016

**Growth capex at ~60% of total
with ~2/3rd in Advanced Materials**

- Aerospace investments
- PEEK plant in US
- Fluoropolymer plant in China, phase 2
- HPPO plant in Saudi Arabia

**Capex discipline
to reduce capital intensity**

- Strategic fit
- IRR ≥ 15%


Profit growth
Improved cash conversion

SUSTAINABLE IMPROVEMENT
IN FREE CASH FLOW

SOUND CASH GENERATION

Underlying net debt^[1] evolution

in € m



Strong Free cash flow

- Thanks to REBITDA increase & IWC control
- Despite capex increase with cash conversion^[2] of 50%

Provisions & other OCF

- Taxes of € (245) m
- Movements in provisions including € 119 m pensions (net of service costs)


Other changes in net debt

- M&A other than Cytec of € (208) m mainly taxes on Eco Services disposal in 2014
- Dividends to minorities of € (41) m

INVESTMENT GRADE CREDIT RATINGS CONFIRMED

Underlying net debt^[1]
evolution

in € bn



Leverage ^[3] net debt/REBITDA	Gearing net debt/equity	Underlying	INVESTMENT GRADE RATING	Moody's	S&P	confirmed post acquisition & funding
2.8x	88%			Baa2 negative outlook	BBB- stable outlook	
1.9x	45%	IFRS basis				

Overview

- Transformation acceleration & delivery
- Financial highlights
- **Priorities and Outlook**



SOLVAY

asking more from chemistry®



2016

Priorities

- **Cytec integration, synergies acceleration**
- **Volume growth**
- **Excellence initiatives**
- **Intensified focus on cash generation**
- **Continuing portfolio upgrade**

RAPID & EFFECTIVE SYNERGY REALIZATION

TOTAL SYNERGIES EXPECTED WELL ABOVE ORIGINAL € 100 M

Cost synergies: > €100m by end of 2018

- Corporate overhead and G&A: - € 20 m already captured as of January 1, 2016
- Supply chain & procurement
- Excellence practices

Revenue synergies: Additional upside

- Acceleration of lightweighting opportunities across Specialty Polymers & Composite Materials
- Cross-selling opportunities with Advanced Formulations
- More being identified

People synergies: Leveraging talent

- Best practice emulation
- Cross fertilization

HIGHER
—
QUICKER
—
LOW
EXECUTION
RISK

DELIVERING GROWTH IN 2016

Volume growth

- **New Capacity available**
- **Innovation**
- **Debottlenecking**

Cash generation

- **REBITDA growth**
- **Lower capex**
- **Improved cash conversion**

ENABLED BY
EXCELLENCE MEASURES
€ 800 M

(CUMULATIVE BY END 2016 VS 2013)

ADVANCED MATERIALS

- Growth in diversified markets to overcome Q1 inventory destocking in smart devices
- Continued growth from ramp-up of aircraft with higher composites content

ADVANCED FORMULATIONS

- Growth in health, personal care, agro and Technology Solutions businesses ...
- ... to offset continuing oil & gas market weakness

PERFORMANCE CHEMICALS

- New Bicarbonate plant in Thailand
- Return to growth in acetate tow

FUNCTIONAL POLYMERS

- Growth in Engineering Plastics' downstream applications



**REBITDA
to grow high single digits**

Growth to be back-ended

**Free cash flow
to exceed € 650 m**

REWARDING SHAREHOLDERS


SOLVAY GROSS DIVIDEND 2015

Interim dividend € **1.36** / share Paid on January 21, 2016

Final dividend^[1] € **1.94** / share To be paid on May 17, 2016

Total^[1] € **3.30** / share **Up 3.3%**^[2]

DELIVERY ON COMMITMENTS



For >30 years

5.7% DPS CAGR

~40% average pay-out



Committed to stable / growing dividend

OUR COMMITMENT



Exceed expectations on Cytec synergies

Excellence & Portfolio optimization continuing

Intensified focus on cash generation

Attractive returns to shareholders

INVESTOR RELATIONS



Maria Alcón-Hidalgo

+32 2 264 1984
maria.alconhidalgo@solvay.com



Jodi Allen

+1 (973) 357 3283
jodi.allen@solvay.com



Geoffroy Raskin

+32 2 264 1540
geoffroy.raskin@solvay.com



Bisser Alexandrov

+32 2 264 3687
bisser.alexandrov@solvay.com



NEXT EVENTS

**May 3
2016**

Q1 2016
results

**May 10
2016**

Annual general
meeting

**May 17
2016**

Final dividend payment

- ex-coupon date: 13/05
- record date: 16/05

**July 29
2016**

Q2 & H1 2016
results

**November 8
2016**

Q3 2016
results

Appendix


- 2015 FY Solvay stand-alone segment information
- Additional 2015 FY financial data
- Solvay pro forma information
- Forex sensitivity & other financial considerations






SOLVAY

asking more from chemistry®


STRONG REBITDA GROWTH IN 2015 IN 3 OUT OF 4 SEGMENTS



Innovation mitigating
major O&G market adjustments





Excellence-driven
margin expansion



ADVANCED FORMULATIONS FY 2015 PERFORMANCE


OIL & GAS HEADWINDS OFFSET IMPROVEMENT OTHER MARKETS

Net sales (in € m)



■ Novecare ■ Coatis ■ Aroma Performance

REBITDA (in € m)



Market contraction in **Novecare's** oil & gas activities

- Sharp fall in unconventional North American oil & gas markets continuing
- Cementing, drilling and stimulation subsectors down; production subsector resilient though
- Innovation delivery, competitiveness actions mitigate price pressure and reduces fixed costs
- Good developments in agro, coatings and HPC

Coatis supported by forex

- Weak domestic demand in Latin America
- BRL weakness underpinned competitive position


Volume growth in **Aroma Performance**

- Strong volume growth in vanillin and hydroquinone inhibitors
- Strong industrial performance following production issues in 2014


ADVANCED MATERIALS FY 2015 PERFORMANCE

INNOVATION-DRIVEN REBITDA RECORD

Net sales (in € m)



REBITDA (in € m)



Specialty Polymers' growth driven by innovative products

- Higher volumes, supportive forex and pricing power led to another strong performance
- Demand in smart devices, automotive and other high-end applications was strong
- Only at year end a more moderate growth on sales phasing in smart devices was observed

Volume growth and good pricing at Silica

- Strong sales benefitted from price and volume increases
- Demand for energy-efficient tires in Europe and North America growing, whereas Asia's macro context subdued
- New plant in Poland in qualification process



Good dynamics at Special Chem

- Good volume growth in rare earth compounds (mainly for automotive diesel catalysts), fluor specialties and electronic materials
- The new high-purity H2O2 units in the U.S. are ramping up


PERFORMANCE CHEMICALS FY 2015 PERFORMANCE

PRICING OFFSET DESTOCKING HEADWINDS IN ACETOW

Net sales (in € m)



REBITDA (in € m)



Strong pricing at Soda Ash & Derivatives

- Successful pricing strategy in soda ash underpinned by ongoing excellence programs
- Overall sales volumes stable
- Bicarbonate sales up; New Thai plant ramping up since September

Strong performance at Peroxides

- Net pricing gains on higher average sales prices and energy prices
- Sales volumes stable
- HPPO mega plants at high capacity rates

Destocking persists in Acetow's market

- Destocking in the acetate tow market persisted, although situation improved in H2'15
- Positive net pricing underpinned by forex



Emerging Biochemicals up on volumes and forex

- Good performance on favorable forex and excellence programs
- Higher volumes from PVC exports out of Thailand offset lower pricing
- Epicerol® volumes stable


FUNCTIONAL POLYMERS FY 2015 PERFORMANCE

EXCELLENCE-DRIVEN PROFIT RESTORATION

Net sales (in € m)



REBITDA (in € m)



Operating performance well up in **Polyamide**

- Strong net pricing on excellence programs implemented in the PA6.6 upstream businesses, lower raw materials prices as well as positive transaction forex effects
- Volumes were flat overall
- Poor economic conditions persist in Brazil, Fibras' home market


Chlorovinyls' result up yoy

- The ramp-up of RusVinyl JV in Russia contributed positively to the operational result
- INOVYN contribution included since Q3, but only reflecting mark-to-market of exit fee

CORPORATE & BUSINESS SERVICES FY 2015 PERFORMANCE

COSTS UP DUE TO CER IMPAIRMENT AND FOREX IMPACT

REBITDA (in € m)



Corporate & Business Services

<i>in € m</i>	FY 2015	FY 2014
Energy Services	(3)	25
Of which one-offs	(7)	CER impairment
Excluding one-offs	4	25
Other C&BS	(186)	(213)
Of which one-offs	30	U.S. post-retirement Medicare insurance
Excluding one-offs	(216)	(213)
Total	(189)	(188)

Contribution from Energy Services down

- Poor contribution of Energy Services € (3) m or € (28) m lower than in 2014
- Difficult conditions for investments in biomass-based energy plants as well as the energy and carbon management services in a low commodity price environment
- In Q3 2015 a € (7) m one-off impairment on outstanding carbon emission rights in Brazil was booked

Other Corporate & Business Services


- Better year on year performance linked to back-end loaded cost phasing in 2014 and continued excellence measures offsetting the adverse impact of exchange rates and inflation
- In Q1 2015 a one-off benefit of € 30 m linked to the evolution of the post-employment Medicare insurance policy in the U.S. was booked

WORKING CAPITAL DISCIPLINE MAINTAINED

Industrial working capital^[1]

Solvay stand-alone

% of total sales




→ Superior specialty businesses growth
increased industrial working capital needs

Committed to further optimization

DEBT PROFILE

BALANCED MATURITIES ALLOWING FLEXIBILITY




	Face value	Average duration ^[1]	Average cost	Legend
Existing debt	2,500	3.1	5.0%	<div>Existing EUR hybrid bonds (at 1st call date) including € 500 m 6.38% 2016 treated as debt</div> <div>Existing EUR bonds (G other major debt)</div>
Cytec debt	673	7.4	4.3%	<div>Cytec USD bonds</div>
New debt	4,720	6.6	3.1%	<div>New EUR hybrid bonds (at 1st call date)</div> <div>New USD bonds</div> <div>New EUR bonds</div>
Total major debt	7,892	5.6	3.8%	
	in € m	in years		

PENSION LIABILITIES

Pensions (31/12/2015)

in € bn



Cash contribution of € (168) m in 2015

- vs € (180) m in 2014

Pension assets of € 2.9 bn


- Up € 0.8 bn vs 30/09/14 mainly due to Cytec acquisition
- ~50% Equities / Diversified alternative funds
- ~50% Bonds / Real estate

Net pension liabilities up € 0.1 bn to € 3.0 bn

- € 206 m or 7.0% of total net liability is due to Cytec
- France, Germany and UK relative weight decreased while North America increased after Cytec acquisition.

Net pension liabilities (31/12/2015)

in € bn




All presented figures are for continuing operations only

Discount rates^[1] increased in 2015

Currency	31/12/2015	31/12/2014	Change	Average duration
EUR	2.25%	1.75%	0.50pp	13.1 years
GBP	3.75%	3.50%	0.25pp	16.4 years
USD	4.25%	4.00%	0.25pp	11.6 years
Weighted average	3.30%	2.71%	0.59pp	13.7 years

[1] Average discount rate on post employment benefit related liabilities applicable to high quality corporate bonds in EUR, GBP and USD zones

SOLVAY REALIGNED BUSINESS SEGMENTS INCLUDING CYTEC STRATEGICALLY COHERENT TO DRIVE RESULTS



Market positions:

- #X Global market position in main markets addressed
- #X Regional market position in main markets addressed

2015 pro forma GROUP

Net sales	€ 12,378 m
REBITDA	€ 2,336 m
margin	19%
CFROI	6.1%

GROWTH ENGINES

ADVANCED MATERIALS

High performance materials, providing solutions for sustainable mobility: **light-weighting**, CO₂ and energy efficiency

Specialty Polymers #1

Composite Materials #2

Special Chem #1

Silica #1

ADVANCED FORMULATIONS

Customized specialty formulations in **surface chemistry**, optimizing efficiency, minimizing environmental impact

Novecare #1

Technology Solutions #1

Aroma Performance #1

RESILIENT CASH CONTRIBUTOR

PERFORMANCE CHEMICALS

Leading positions in chemical intermediates, through scale and technology

Soda Ash & Derivatives #1

Peroxides #1

Acetow #4

Coatis #1

FUNCTIONAL POLYMERS

Leading regional positions in functional polymers, with focus on excellence

Polyamide #3

Chlorovinyls #2

2015 pro forma	GROUP	Advanced Materials	Advanced Formulations	Performance Chemicals	Functional Polymers
Net sales	€ 12,378 m	€ 4,503 m	€ 2,855 m	€ 3,052 m	€ 1,926 m
REBITDA	€ 2,336 m	€ 1,079 m	€ 522 m	€ 770 m	€ 190 m
margin	19%	24%	18%	25%	10%
CFROI	6.1%	8.2%	5.7%	8.5%	3.5%


FOREX IMPACTS

Forex sensitivity in 2016

- Immediate impact on conversion exposure
- Deferred transactional impact due to hedging (6-12 month rolling basis)
- Mainly linked to USD
 - **Sensitivity in 2016:**
~ € 130 m REBITDA per (0.10) \$/€
 - Half conversion, half transactional
- Main other currencies exposed to
 - JPY, CNY, THB, BRL, KRW, RUB

Forex development in 2015

- Total conversion impact of € 168 m (~2/3rd from USD/EUR increase)
- Total transactional impact of € 70 m



- Solvay's main currencies through 2015

/€	USD	JPY	RUB	BRL	CNY	KRW	THB
FY 2014	1.33	140.31	50.95	3.12	8.19	1,398	43.15
FY 2015	1.11	134.31	68.07	3.70	6.97	1,257	38.03
Change	-0.22	-5.99	17.12	0.58	-1.21	-142	-5.12
Change in %	-16%	-4%	34%	19%	-15%	-10%	-12%

EBIT(DA) CONSIDERATIONS FOR 2016

Excellence

- Excellence programs on course to reach target
 - € 800 m cumulative benefits by end 2016 vs 2013 cost base
 - > € 600 m delivered in 2014-2015
- Cytec synergies from integration by 2018
 - Cost savings estimated > € 100 m
 - Revenue synergies on top

Depreciation & amortization

- Underlying depreciation & amortization expected at ~€ (800) m (excluding PPA amortization)
- PPA amortization of ~€ (370) m, consisting of PA impacts from Rhodia, Cytec and other smaller acquisitions (Chemlogics, Ryton)

Scope effects

- Acquisitions in 2015
 - Cytec full consolidation as of January 1 2016
 - Small acquisition in 2015: EPIC
- Divestments in 2015
 - Refrigerants in May 2015: net sales of ~€ 50 m in 2014
 - PCC in November 2015: net sales of ~€ 60 m in 2014

Non-recurring elements

- Restructuring costs
- Impairments related to business not under discontinued operations
- HSE provisions on non-operational sites
- Contingencies / litigations
- Portfolio management-related expenses, gains & losses, e.g. Cytec acquisition

UNDERLYING FINANCIAL & TAX P&L CONSIDERATIONS FOR 2016

Cost of borrowings

Total underlying financial charges expected at ~€ (350) m (incl. perpetual hybrid bonds)

- Financial charges from major senior debt (excl. perpetual hybrid bonds)
 - 2016 charges expected at ~€ (150) m
 - Average cost: 2015: 5.2% → 2016: 3.3%
 - EIB loan of € 300 m reimbursed in January 2016
- Coupons from perpetual hybrid bonds (considered as Dividend & Equity under IFRS)
 - 2016 cash out of € (84) m: Q2 € (57) m / Q4 € (27) m
 - From 2017 onwards € (112) m: Q2 € (84) m / Q4 € (27) m
 - Average cost : 5.1%
- Other elements ~€(90-100)m
 - Currency swaps & Other debt in consolidated subsidiaries
 - Financial charges RusVinyl^[2]: ~€ (25) m

Discounting of pensions and HSE

- P&L: ~€ (100) m ($\frac{3}{4}$ - pensions, $\frac{1}{4}$ - HSE)
- Sensitivity to change in discount rates^[1]: ~€ (370) m / 50bp
 - Pensions (in OCI)
 - € zone ~€ 140 m
 - USA ~€ 80 m
 - UK ~€ 133 m
 - Others € 10 m
 - HSE (in P&L): €-zone ~€ 10 m

Tax rate

Underlying tax rate (adjusted for PPA and other factors) expected stable in the low ~30s

OTHER CONSIDERATIONS FOR 2016

Discontinued operations

- Indupa chlorovinyls business in Latin America
 - Strategic intent unchanged
 - Disposal process undergoing
 - ~€ (50) m in CTA to be recycled through P&L at exit
- European chlorovinyls until June 30, 2015

Cash flow elements

- Cash expenses for pensions range of € (180) m - € (200) m
- Capital expenditure of ~€ 950 m
- IWC discipline maintained but growing part of specialty business in portfolio increases needs

Inovyn JV

- Inovyn JV with INEOS Equity accounting from July 1, 2015
- Exit price of € 335 m agreed between the parties
- Exit expected in H2 2016, subject to finalizing . Definitive legal agreements and customary regulatory approvals